Lv1
60 积分 2026-01-21 加入
LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial
2天前
求助中
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
1个月前
已完结
P2.01-51 Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients
1个月前
已完结
皖公网安备34019202002308
